Human serum albumin (HSA) is responsible for a number of biological functions including binding and delivering molecules and substances to the cell. It also plays an important role as antioxidant and transporter of ligands. HSA is widely used in hospitals and clinics to treat a number of diseases such as hemorrhagic shock, hypoproteinemia, serious burn injuries, fetal erythroblastosis, and cirrhotic ascites. In spite of its widespread utility, high safety risks due to limited human donors, persistent supply shortages, and risk associated with the transmission of blood borne contaminants such as viruses, prions, and mycoplasma have led to development of recombinant technology to manufacture HSA from different animal and plant sources.
Increase in shift toward usage of recombinant albumin for a number of applications such as drug formulation, drug delivery, vaccine production, and cell culture media is the major driver of the global recombinant human serum albumin market. HSA has been successfully used as an excipient in the manufacture of vaccines and drugs; however, there still remains risk of transmission of known and new infectious agents such as HIV and hepatitis due to the use of plasma- and blood-derived products. This inherent risk has prompted regulatory authorities across the globe to create a myriad of regulations limiting the use of plasma-derived products and necessitating the need to develop substitute products for human serum albumin in order to minimize the risk of transmission of adventitious agents. In order to overcome these challenges, recombinant albumin has emerged as a suitable alternative to human serum albumin for use as an excipient in the manufacture of biotherapeutics. Apart from avoiding the spread of serum-derived disease agents, it offers advantages such as improved batch-to-batch consistency. These factors are expected to shift demand from traditional human serum albumin to recombinant albumin in the next few years.
Grant of approvals by national regulatory agencies for new recombinant albumin products developed by pharmaceutical and biotechnology companies is another factor contributing to the growth of the global recombinant human serum albumin market. In May 2017, China’s Food and Drug Administration approved the clinical trials of human blood albumin developed from transgenic rice seeds. Wuhan Healthgen Biotechnology Corp. for Human Health, a privately held Chinese firm that develops and commercializes novel animal-free products for pharmaceutical use, invested nearly US$ 29 Mn to support the research. The company expects to launch the product within four to five years and is eyeing extensive quantities of human serum albumin from rice in order to address the significant shortage of human serum albumin in China. In February 2013, MAQUET Cardiopulmonary was granted regulatory approval in Japan for a medical device that uses Recombumin Alpha, a recombinant albumin produced by Albumedix A/S (formerly Novozymes Biopharma) in combination with MAQUET’s Bioline coating. Bioline coating helps to enhance biocompatibility of the extracorporeal circulation system devices such as centrifugal pumps, oxygenators, and filters to reduce the negative effects on blood when it comes into contact with foreign surfaces.
The global recombinant human serum albumin market can be segmented based on source of origin, application, and region. In terms of source of origin, the recombinant human serum albumin market can be divided into plant derived, microbes, and others. Based on application, the global recombinant human serum albumin market can be classified into drug development & drug delivery, vaccine production, component of cell culture media, and others. In terms of application, the recombinant human serum albumin market can be categorized into pharmaceutical & biotechnology industries, research institutes, and others.
In terms of region, the global recombinant human serum albumin market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominates the global recombinant human serum albumin market due to increase in focus of major players to launch new recombinant albumin-based products in the region. In March 2016, CSL Behring announced that it received approval from the U.S. Food and Drug Administration (FDA) for its IDELVION, a novel albumin fusion protein linking recombinant albumin with recombinant coagulation factor IX, to be used in hemophilia B treatment.
Prominent players operating in the global recombinant human serum albumin market are Albumedix A/S (Novozyme A/S), Sigma-Aldrich Co. LLC (Merck KGaA), Medxbio Pte. Ltd., Prospec-Tany TechnoGene Ltd., Albumin Therapeutics, LLC, Wuhan Healthgen Biotechnology Corp., Mitsubishi Tanabe Pharma Corporation, and Thermo Fisher Scientific, Inc.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
With a robust experience in creating exceptional market reports, Transparency Market Research has emerged as one of the trusted market research companies among a large number of stakeholders and CXOs. Every report at Transparency Market Research goes through rigorous research activity in every aspect. The researchers at TMR keep a close watch on the market and extract beneficial growth-boosting points. These points help the stakeholders to strategize their business plans accordingly.
TMR researchers conduct exhaustive qualitative and quantitative research. This research involves taking inputs from the experts in the market, focused attention on recent developments, and others. This method of research makes TMR stand out from other market research firms.
Here's how Transparency Market Research helps the stakeholders and CXOs through the reports:
Inculcation and Evaluation of Strategic Collaborations: The TMR researchers analyze recent strategic activities like mergers, acquisitions, partnerships, collaborations, and joint ventures. All the information is compiled and included in the report.
Perfect Market Size Estimations: The report analyzes the demographics, growth potential, and capability of the market through the forecast period. This factor leads to the estimation of the market size and also provides an outline about how the market will retrieve growth during the assessment period.
Investment Research: The report focuses on the ongoing and upcoming investment opportunities across a particular market. These developments make the stakeholders aware of the current investment scenario across the market.
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.